Printer Friendly

SANDOZ-CIBA GEIGY MERGER WOULD CREATE EIGHTH-LARGEST PHARMACEUTICAL FIRM IN U.S.

TOTOWA, N.J., March 7 /PRNewswire/ -- The following was released today by IMS America:

The announced merger yesterday of Swiss-based Sandoz Ltd. and Ciba-Giegy Ltd. will form the eighth-largest pharmaceutical company in the U.S., according to IMS America. IMS, a division of The Dun & Bradstreet Corporation, is the leading provider of marketing, sales, management and medical information for the American pharmaceutical industry.

Combined Company: 4.5 per Market Share

Figures released by IMS today estimate 1995 U.S. sales for the combined companies at just under $3,518,000,000 or 4.5 percent of the total market (Table 2). This volume, which primarily reflects prescription drug sales, would push the proposed new entity ahead of Eli Lilly and Company among the 10 largest U.S. pharmaceutical companies just behind Abbott Laboratories.

IMS data listing the companies separately (Table 1) put Ciba Geigy 12th among U.S. drug firms in 1995 with sales of $2,101,426,000, a 2.7 percent market share. Sandoz ranked 17th with sales of $1,416,712,000, a 1.8 percent share.

Regarding specific drugs (Table 3), IMS reports that Sandoz had two prescription products with U.S. sales over $200 million in 1995 -- Sandimmune, an immunosuppressive, at $291,335,000 and Clozaril, an anti-psychotic drug, at $216,570,000. Ciba had one $200-million-plus drug -- Voltaren, an NSAID, at $232,512,000.

Sandimmune is the only drug marketed by either firm to rank in the top 50 in Rx sales last year. It ranked 42nd. However, several Ciba and Sandoz products grew dramatically in 1995, led by Sandoz's cholesterol-reducing drug, Lescol. This drug's sales of $145,061,000 represent a 251 percent increase over 1994. Next in growth among Sandoz's top-selling drugs was the dermatological anti-fungal, Lamisil, up 21 percent over last year,

Ciba's Growth Leaders

Increases of note among Ciba's top-selling products in 1995 came from Triamterene/HCTZ, Cataflam, Lotensin, Lopressor, Ritalin and Habitrol. Triamterene/HCTZ, a generic diuretic, was up 61 percent over '94; Cataflam, an NSAID, was up 56 percent, while Lotensin and Lopressor, both hypertension treatments, were up 38 percent and
36 percent respectively. Sales of Ritalin, the leading drug for treating Attention Deficit Disorder, increased 29 percent, and those of Habitrol, a smoking-cessation patch, increased 21 percent.


The U.S. headquarters of both companies are in New Jersey -- Ciba Geigy in Summit and Sandoz in East Hanover.

IMS databases for prescription sales includes virtually all prescription products purchased by six distribution pharmacy channels -- independents, chain stores, food stores, clinics, long-term care facilities, staff-model HMOs and Federal government hospitals.

Table 1: Rankings with Ciba-Geigy and Sandoz Separate

Top 20 Leading Pharmaceutical Corporations

Total U.S. Market 1995
 1995 RANKING CORPORATION $ SALES (000s) % OF TOTAL MARKET
 1 Glaxo Wellcome $5,570,535 7.2%
 2 American Home
 Products 4,729,133 6.1
 3 Bristol-Myers Squib 4,726,643 6.1
 4 Johnson & Johnson 4,480,432 5.8
 5 Merck & Company 4,181,100 5.4
 6 Pfizer 3,877,903 5.0
 7 Abbott 3,755,556 4.9
 8 Lilly 3,305,532 4.3
 9 SmithKline Beecham 3,062,045 4.0
 10 Schering Plough 2,798,685 3.6
 Total Leading 10
 Corporations 40,487,565 52.3
 11 Hoffman LaRoche 2,128,158 2.8
 12 Ciba-Geigy 2,101,426 2.7
 13 Marion Merrell Dow 2,080,495 2.7
 14 Bayer 1,780,421 2.3
 15 Amgen Inc. 1,565,782 2.0
 16 The Upjohn Company 1,425,833 1.8
 17 Sandoz 1,415,712 1.8
 18 Private Label 1,285,223 1.7
 19 Astra Merck 1,265,669 1.6
 20 Rhone-Poulenc 1,251,631 1.6
 Total Leading 20
 Corporations 56,787,916 73.4
 TOTAL ALL CORPORATIONS $77,383,921 100.0%


Source: IMS America

Table 2: Rankings with Ciba-Geigy and Sandoz Combined
 Top 10 Leading Pharmaceutical Corporations
 Total U.S. Market 1995
 1995 RANKING CORPORATION $ SALES(000s) % OF TOTAL MARKET
 1 Glaxo Wellcome $5,570,535 7.2%
 2 American Home
 Products 4,729,133 6.1
 3 Bristol-Myers
 Squib 4,726,643 6.1
 4 Johnson & Johnson 4,480,432 5.8
 5 Merck & Company 4,181,100 5.4
 6 Pfizer 3,877,903 5.0
 7 Abbott 3,755,556 4.9
 8 Ciba-Geigy/Sandoz 3,517,138 4.5
 9 Lilly 3,305,532 4.3
 10 SmithKline
 Beecham 3,062,045 4.0
 Total Leading 10
 Corporations 41,206,018 53.3
 TOTAL ALL
 CORPORATIONS $77,383,921 100.0%


Source: IMS America

Table 3: Ciba/Sandoz Combined Sales
 Top-Selling Pharmaceuticals -- Total U.S. Market 1995
 DRUG COMPANY $ SALES (000S) % CIBA/SANDOZ %Growth
 TOTAL SALES (1994 to
 1995)
 Sandimmune Sandoz 291,335 8.3 +8
 Voltaren Ciba-Geigy 232,512 6.8 -13
 Clozaril Sandoz 216,570 6.2 +18
 Lescol Sandoz 145,061 4.1 +251
 Tegretol Ciba-Geigy 137,799 3.9 +5
 Lotensin Ciba-Geigy 128,889 3.7 +38
 Estraderm Ciba-Geigy 103,354 2.9 - 3
 Lopressor Ciba-Geigy 98,859 2.8 -36
 Ritalin Ciba-Geigy 95,644 2.7 +29
 Cataflam Ciba-Geigy 87,368 2.5 +58


Triamterene/
 HCTZ Ciba-Geigy 78,957 2.2 +61
 DynaCirc Sandoz 78,253 2.2 - 3


Transderm-
 Nitro Ciba-Geigy 72,726 2.1 -14
 Fiorinal Sandoz 70,083 2.0 - 5
 Sandoglobulin Sandoz 69,002 2.0 +9
 Parlodel Sandoz 68,196 1.9 -14
 Habitrol Ciba-Geigy 54,638 1.6 -21
 Anafranil Ciba-Geigy 48,200 1.4 - 5
 Actigall Ciba-Geigy 40,139 1.1 +15
 Lamisil Sandoz 39,350 1.1 +29
 Total Others Ciba/Sandoz 1,360,182 38.7 --
 TOTAL Ciba/Sandoz 3,517,138 100.0 +5


Source: IMS America
 -0- 3/7/96


/CONTACT: Robert Merold of IMS America, 201-904-6440; or Nicole Gavino or Bill Noonan of Princeton PR Group, 908-508-1313/

CO: Sandoz Ltd.; Ciba-Geigy Ltd. ST: New Jersey IN: HEA MTC SU: TNM

DW -- NYTH093 -- 1329 03/07/96 17:04 EST
COPYRIGHT 1996 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1996 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 7, 1996
Words:998
Previous Article:PROPANE SYSTEMS AVAILABLE ON 1996 FORD F-SERIES
Next Article:HEALTHCARE IMAGING SERVICES, INC. REPORTS 1995 FINANCIAL RESULTS
Topics:

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters